Feasibility of Early Gabapentin as an Intervention for Neurorecovery
Key facts
- Who runs it
- MetroHealth Medical Center
- Where
- Cleveland, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 26 people enrolled
- Started
- 14 Mar 2022
- Ended
- 31 Mar 2026
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Gabapentin
- Placebo
- Record updated
- 1 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Traumatic SCI
- All levels of SCI
- All severities of SCI, AIS A-D
- Age 18 years and older
- Agree to participate and start study drug within 120 hours' post-injury
- Adequate cognition and communication to provide informed consent
Who cannot take part
- Presence of moderate/severe traumatic brain injury (TBI) as defined by Glasgow Coma Score (GCS) < 13 at 120 hours' post-injury
- Documented use of gabapentinoids at the time of injury
Where in United States
- MetroHealth Medical CenterCleveland, United States
About the trial
What the trial wants to find out
The objective of the proposed study is to conduct the first ever prospective, dose-exploration trial to test the feasibility of early administration of gabapentin as an intervention for neurorecovery. This research project falls under the Intervention Development stage of research as the primary goal is to assess the feasibility of conducting a well-designed intervention efficacy study in the future.
The 3 groups in the trial
- Low doseTreatment being tested
600mg treatment group will receive 2 capsules of gabapentin by mouth 3 times per day for 90 days.
Treatment: Gabapentin
- Medium doseTreatment being tested
1800 mg treatment groups will receive 2 capsules of gabapentin by mouth 3 times per day for 90 days.
Treatment: Gabapentin
- ControlPlacebo, for comparison
The control group will receive 2 placebo capsules of inert cellulose by mouth 3 times per day for 90 days.
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Feasibility of gabapentin as an intervention for neurorecovery after an acute spinal cord injury: Protocol.Frontiers in neurology, 2022
- Record updated
- 1 October 2026